MADISON, WI - February 12, 2004- NimbleGen Systems, Inc., producer of custom high-density DNA microarrays using proprietary Maskless Array Synthesis (MAS) technology, announced the appointments of Emile Nuwaysir, Ph.D. as the Vice President of Business Development and Dan Clutter, Ph.D. as the Vice President of Sales.

Dr. Nuwaysir was one of the first NimbleGen employees and has held various research and managerial positions within the company. Prior to NimbleGen, he held a Postdoctoral Fellowship with the National Institute of Environmental Health Sciences (NIEHS) within the National Institutes of Health (NIH), where he helped coordinate the development of the NIEHS Microarray Core Facility and developed ToxChip, a microarray used by the NIEHS and the National Center for Toxicogenomics in their human toxicology studies. He earned his Ph.D. in Environmental Toxicology with a focus in Oncology from the University of Wisconsin-Madison in the McArdle Laboratory for Cancer Research.

Dr. Clutter comes to NimbleGen with over 20 years of experience in the biotechnology marketplace in research, sales, and marketing. He gained experience at small startup companies as well as PerkinElmer, ABI, Celera, PanVera and Invitrogen. He received a B.S. in Biochemistry from Purdue University and a Ph.D. from Pennsylvania State University.

Stan Rose, Ph.D., President and CEO, said, "These two appointments are key moves in transitioning the Company from a technology-development organization to a commercially-focused entity. Over the course of 2004 we will be significantly expanding our sales, marketing and business development capabilities, and I'm delighted to have Dan and Emile leading these activities."

About NimbleGen Systems Inc.
NimbleGen Systems provides customized high-density microarray products and services with unprecedented flexibility for functional genomics experiments. NimbleGen's technology combines photo-deposition chemistry with digital light projection to shorten array fabrication from months to less than three hours, and NimbleGen scientists are aggressively developing and deploying new microarray applications to speed discovery research. Customers benefit from extreme flexibility, optimized array design, highly reproducible array fabrication and statistically robust results-all with low cost and quick turnaround.